drugset / Trial / NCT00103571

Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

NCT00103571

Phase 4 Completed 600 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

Timeline

Start
2004-07
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified
Subject Olanzapine Small molecule

Indications